Sangamo Biosciences's total assets for Q3 2024 were $111.26M, an increase of 19.62% from the previous quarter. SGMO total liabilities were $72.13M for the fiscal quarter, a 4.05% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.